Biot-PVKRRLDL-OH

Ref. 3D-PP45170

Informations sur le produit

• Nom: Biot-PVKRRLDL-OH
• Synonymes: Biot-Pro-Val-Lys-Arg-Arg-Leu-Asp-Leu-OH

Description

Peptide Biot-PVKRRLDL-OH is a Research Peptide with significant interest within the field academic and medical research. This peptide is available for purchase at Cymit Quimica in multiple sizes and with a specification of your choice. Recent citations using Biot-PVKRRLDL-OH include the following: Selective killing of transformed cells by cyclin/cyclin-dependent kinase 2 antagonists YNP Chen , SK Sharma, TM Ramsey - Proceedings of the , 1999 - National Acad Scienceshttps://www.pnas.org/doi/abs/10.1073/pnas.96.8.4325 Cell cycle-dependent nuclear retention of p53 by E2F1 requires phosphorylation of p53 at Ser315 V Fogal, JK Hsieh, C Royer, S Zhong, X Lu - The EMBO journal, 2005 - embopress.orghttps://www.embopress.org/doi/abs/10.1038/sj.emboj.7600735 Structural and functional analysis of cyclin D1 reveals p27 and substrate inhibitor binding requirements S Liu , JK Bolger, LO Kirkland, PN Premnath - ACS chemical , 2010 - ACS Publicationshttps://pubs.acs.org/doi/abs/10.1021/cb1001262 Identification of a cyclin-cdk2 recognition motif present in substrates and p21-like cyclin-dependent kinase inhibitors PD Adams, WR Sellers , SK Sharma - and cellular biology, 1996 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1128/mcb.16.12.6623 Molecular horizons of cancer therapeutics: 11th Pezcoller symposium ML Avantaggiati - Biochim Biophys Acta, 2000 - researchgate.nethttps://www.researchgate.net/profile/Maria-Avantaggiati/publication/12517266_Molecular_horizons_of_cancer_therapeutics_11th_Pezcoller_symposium/links/5c1ee7dfa6fdccfc7062972a/Molecular-horizons-of-cancer-therapeutics-11th-Pezcoller-symposium.pdf A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells ME Lane , B Yu, A Rice, KE Lipson, C Liang, L Sun - Cancer research, 2001 - AACRhttps://aacrjournals.org/cancerres/article-abstract/61/16/6170/507818 Cyclin-dependent kinase inhibition: an opportunity to target protein-protein interactions MA Klein - Advances in Protein Chemistry and Structural Biology, 2020 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1876162319300902 Targeting cyclin-dependent kinases in human cancers: from small molecules to peptide inhibitors M Peyressatre, C Prevel, M Pellerano, MC Morris - Cancers, 2015 - mdpi.comhttps://www.mdpi.com/2072-6694/7/1/179 ATP-Noncompetitive Inhibitors of CDK-Cyclin Complexes M Orzaez, A Gortat, L Mondragon - ChemMedChem , 2009 - Wiley Online Libraryhttps://chemistry-europe.onlinelibrary.wiley.com/doi/abs/10.1002/cmdc.200800185 Anticancer therapeutic strategies based on CDK inhibitors L Esposito, P Indovina , F Magnotti - Current , 2013 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/cpd/2013/00000019/00000030/art00002 The design, synthesis and evaluation of guanidine-based molecular transporters K Pattabiraman - 2004 - search.proquest.comhttps://search.proquest.com/openview/03f7f381d55a78dc589eafbbdf09c474/1?pq-origsite=gscholar&cbl=18750&diss=y Cell-penetrating peptides, electroporation and drug delivery K Cahill - IET Systems Biology, 2010 - IEThttps://digital-library.theiet.org/content/journals/10.1049/iet-syb.2010.0007 Inhibition of the cell cycle with chemical inhibitors: A targeted approach JPI Welburn , JA Endicott - Seminars in cell & developmental biology, 2005 - Elsevierhttps://www.sciencedirect.com/science/article/pii/S1084952105000327 Novel function of the cyclin A binding site of E2F in regulating p53-induced apoptosis in response to DNA damage JK Hsieh, D Yap , DJ O'Connor, V Fogal - and cellular biology, 2002 - Taylor & Francishttps://www.tandfonline.com/doi/abs/10.1128/mcb.22.1.78-93.2002 In vitro assays: friends or foes of cell-penetrating peptides J Liu, S Afshar - International Journal of Molecular Sciences, 2020 - mdpi.comhttps://www.mdpi.com/1422-0067/21/13/4719 Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases. H Hirai, N Kawanishi, Y Iwasawa - Frontiers in Medicinal , 2010 - books.google.comhttps://books.google.com/books?hl=en&lr=&id=N_luK703FKEC&oi=fnd&pg=PA347&dq=(%22Biot-Pro-Val-Lys-Arg-Arg-Leu-Asp-Leu-OH%22+OR+%22PVKRRLDL%22+OR+%22Biot-PVKRRLDL-OH%22)+AND+peptide&ots=bcrhIU7QIB&sig=_Kbx69xgQAIi8wLO8F8aBol59b0 Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases H Hirai, N Kawanishi, Y Iwasawa - Current topics in medicinal , 2005 - ingentaconnect.comhttps://www.ingentaconnect.com/content/ben/ctmc/2005/00000005/00000002/art00006 Medium-sized peptides as built in carriers for biologically active compounds F Hudecz , Z Banoczi , G Csaca­k - Medicinal research reviews, 2005 - Wiley Online Libraryhttps://onlinelibrary.wiley.com/doi/abs/10.1002/med.20034 Preclinical and clinical development of cyclin-dependent kinase modulators AM Senderowicz, EA Sausville - Journal of the National Cancer , 2000 - academic.oup.comhttps://academic.oup.com/jnci/article-abstract/92/5/376/2606689 Specific kinase inhibition using peptides to target kinase-substrate docking AD Cunningham, N Qvit - Chim. Oggi/Chem. Today, 2016 - researchgate.nethttps://www.researchgate.net/profile/Nir-Qvit/publication/313026051_Specific_kinase_inhibition_using_peptides_to_target_kinase-substrate_docking/links/588d3c22a6fdcc8e63c982df/Specific-kinase-inhibition-using-peptides-to-target-kinase-substrate-docking.pdf

• Marque: Biosynth